Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Losartan Effects on the Extinction of Conditioned Fear in Humans

Trial Profile

Losartan Effects on the Extinction of Conditioned Fear in Humans

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2018

At a glance

  • Drugs Losartan (Primary)
  • Indications Diabetic nephropathies; Heart failure; Hypertension
  • Focus Pharmacodynamics
  • Most Recent Events

    • 04 Jun 2018 Planned End Date changed from 31 Jul 2018 to 31 Dec 2018.
    • 04 Jun 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Oct 2018.
    • 15 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top